Sinotau Pharmaceutical Group
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING5
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| XTR006 NCT07115238 |
P3 | Recruiting | Alzheimer Disease; Neurofibrillary Tangle | 354 | 2025-12-31 |
| STB-XTR-003 NCT07443696 |
P2 | Recruiting | Ischemic Cardiomyopathy; Heart Failure | 40 | 2026-12-31 |
| XTR004 NCT07439133 |
P3 | Recruiting | Coronary Artery Disease(CAD) | 395 | 2027-06 |
| Lutetium[177Lu] Oxodotreotide Injection NCT06398444 |
P2/3 | Recruiting | Advanced Neuroendocrine Neoplasm | 85 | 2027-06-01 |
| Phase I:[177Lu]Lu-XT033 Injection NCT06081686 |
P1/2 | Recruiting | Prostate Cancer | 32 | 2027-12-31 (+25 mo) |